Honghui Capital Invests in Korean CRO MediTip's Pre-IPO Round

Recently,HLCSuccessfully completed the engagement with South Korea's leading CRO companyMediTip Co., Ltd.(hereinafter referred to as “MediTip Co., Ltd.”) pre-IPO financing round. The funds participating in this round include:Korea JC Asset Management、Korea JL Partnersetc.

MEDITIPCompanyEstablished in 2007 and headquartered in Seoul, South Korea, MediTip Co., Ltd. boasts over 17 years of experience in regional and international multi-center clinical trials, having participated in more than 1,500 registration projects for pharmaceuticals and medical devices. Leveraging its professional services and extensive expertise, the company provides clients with one-stop solutions ranging from study design and regulatory submission strategies to operational execution and quality assurance, committed to delivering high-quality clinical support to South Korean biopharmaceutical and medical device companies. Amidst the global wave of drug research and development, China and South Korea are playing increasingly pivotal roles.

MediTip Co., Ltd.Committed to expanding cooperation between China and South Korea in the field of clinical research, jointly promoting the development of clinical trial research and the sharing of clinical resources. Meanwhile, the company assists Chinese and South Korean biopharmaceutical enterprises in expanding into international markets, facilitating a deeper understanding on both sides of each other’s new drug clinical trial trends, updates to regulatory policies, and clinical development strategies tailored to their respective national contexts.